Skip to main content

Advertisement

SpringerLink
Log in

Gene Therapy for Hypertension

A Review of Potential Targets

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Somatic gene delivery approaches have received wide attention as a new technique for studying gene expression and as a potential therapeutic tool in treating both inherited and acquired diseases. Recent studies using nonviral and viral vectors have shown great promise for gene therapy in hypertensive diseases. Potential targets for prospective gene therapy in hypertension include vasopressor renin-angiotensin system components and a number of vasodilator polypeptides such as tissue kallikrein-kinin, atrial natriuretic peptide, adrenomedullin and nitric oxide synthase.

Antisense inhibition with oligonucleotides or cDNAs encoding renin, angiotensinogen, angiotensin-converting enzyme and angiotensin receptors has been shown to cause a prolonged blood pressure reduction in spontaneously hypertensive rats. To evaluate the therapeutic potential of vasodilator proteins or peptides in high blood pressure, we delivered the genes encoding human tissue kallikrein, atrial natriuretic peptide, nitric oxide synthase, and adrenomedullin into hypertensive rat models and showed that a single injection resulted in a significant and sustained reduction of blood pressure for several weeks. The potency and duration of blood pressure reduction depends on the dose and the promoter of the gene administered, age and sex of the hypertensive animals as well as the vehicle used for gene delivery. Somatic gene transfer of human tissue kallikrein or atrial natriuretic peptide not only attenuated hypertension but also exerted a protective effect against salt-induced renal damage and cardiac hypertrophy in Dahl salt-sensitive rats after high salt loading.

These results suggest that the application of antisense inhibition of vasopressors, or gene delivery of vasodepressors for gene therapy, may have potential in treating human hypertension, and cardiovascular and renal disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wilson PW. An epidemiologic perspective of systemic hypertension, ischemic heart disease, and heart failure. Am J Cardiol 1997; 80 (9B Special Issue 51): J3–8

    Article  Google Scholar 

  2. Proven Strategies in Prevention and Treatment of Hypertension meeting: 1996 Oct 24–25; Turnberry Isle Resort, Aventura (FL)

  3. Phillips MI, Gyurko R. Antisense oligonucleotides: new tools for physiology. News Physiological Sci 1997; 12: 99–105

    CAS  Google Scholar 

  4. Chao J, Chao L. Experimental kallikrein gene therapy in hypertension, cardiovascular and renal diseases. Pharmacol Res 1997; 35(6): 517–22

    Article  PubMed  CAS  Google Scholar 

  5. Linz W, Wiemer G, Gohlke P, et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25–49

    PubMed  CAS  Google Scholar 

  6. Wielbo D, Simon A, Phillips MI, et al. Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. Hypertension 1996; 28: 147–51

    Article  PubMed  CAS  Google Scholar 

  7. Lu D, Yang H, Raizada MK. Attenuation of ANG II actions by adenovirus delivery of AT1 receptor antisense in neurons and SMC. Am J Physiol 1998; 274: H719–27

    PubMed  CAS  Google Scholar 

  8. Fukamizu A, Sugimura K, Takimoto E, et al. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 1993; 268: 11617–21

    PubMed  CAS  Google Scholar 

  9. Wielbo D, Sernia C, Gyurko R, et al. Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension 1995; 25: 314–9

    Article  PubMed  CAS  Google Scholar 

  10. Tanimoto K, Sugiyama F, Goto Y, et al. Angiotensinogen-deficient mice with hypotension. J Biol Chem 1994; 269: 31334–7

    PubMed  CAS  Google Scholar 

  11. Davisson RL, Kim HS, Krege JH, et al. Complementation of reduced survival, hypotension, and renal abnormalities in angiotensinogen-deficient mice by the human renin and human angiotensinogen genes. J Clin Invest 1997; 99: 1258–64

    Article  PubMed  CAS  Google Scholar 

  12. Sinnayah P, Mckinley MJ, Coghlan JP. Angiotensinogen antisense oligonucleotides and fluid intake. Clin Exp Hyperten 1997; 19: 993–1007

    Article  CAS  Google Scholar 

  13. Krege JH, John SW, Langenbach LL, et al. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 1995; 375: 146–8

    Article  PubMed  CAS  Google Scholar 

  14. Esther CR, Marino EM, Howard TE, et al. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 1997; 99: 2375–85

    Article  PubMed  CAS  Google Scholar 

  15. Callahan MF, Li P, Ferrario CM, et al. Salt-sensitive hypertension in (mREN-2)27 transgenic rats. Hypertension 1996; 27: 573–7

    Article  PubMed  CAS  Google Scholar 

  16. Rohmeiss P, Beyer C, Hocher B, et al. Osmotically induced natriuresis and blood pressure response involves angiotensin AT (1) receptors in the subfornial organ. J Hypertens 1995; 13: 1399–1404

    Article  PubMed  CAS  Google Scholar 

  17. Li P, Morris M, Diz DI, et al. Role of paraventricular angiotensin AT1 receptors in salt-sensitive hypertension in mRen-2 transgenic rats. Am J Physiol 1996; 270: R1178–81

    PubMed  CAS  Google Scholar 

  18. Phillips MI. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Hypertension 1997; 29: 177–87

    Article  PubMed  CAS  Google Scholar 

  19. Gyurko R, Tran D, Phillips MI. Time course of inhibition of hypertension by antisense oligoneucleotides targeted to AT(1) angiotensin receptor mRNA in spontaneously hypertensive rats. Am J Hyperten 1997; 10 (5 Part 2) Pt 2: S56–62

    Article  Google Scholar 

  20. Lu D, Raizada MK, Iyer S, et al. Losartan versus gene therapy — chronic control of high blood pressure in spontaneously hypertensive rats. Hypertension 1997; 30: 363–70

    Article  PubMed  CAS  Google Scholar 

  21. Philips MI, Mohuczydominiak D, Coffey M, et al. Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT(1)-R mRNA antisense. Hypertension 1997; 29: 374–80

    Article  Google Scholar 

  22. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44: 1–80

    PubMed  CAS  Google Scholar 

  23. Yang HYT, Erdös EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 1970; 214: 374–6

    Article  PubMed  CAS  Google Scholar 

  24. Margolius HS. Tissue kallikreins and kinins: regulation and roles in hypertensive and diabetic diseases. Ann Rev Pharmacol Toxicol 1989; 29: 343–64

    Article  CAS  Google Scholar 

  25. Margolius HS, Geller R, de Jong W, et al. Altered urinary kallikrein excretion in human hypertension. Lancet 1971; II: 1063–5

    Article  Google Scholar 

  26. Zinner SH, Margolius HS, Rosner B, et al. Stability of blood pressure rank and urinary kallikrein concentration in childhood: an eight year follow-up. Circulation 1978; 58: 908–15

    Article  PubMed  CAS  Google Scholar 

  27. Berry TD, Hasstedt SJ, Hunt SC, et al. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 1989; 17: 242–6

    Google Scholar 

  28. Overlack A, Stumpe KO, Kolloch R, et al. Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study. Hypertension 1981; 3: 118–21

    Google Scholar 

  29. Wang J, Xiong W, Yang Z, et al. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 1994; 23: 236–43

    Article  PubMed  CAS  Google Scholar 

  30. Song Q, Chao J, Chao L. High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model. Clin Exp Hypertens 1996; 18: 975–93

    Article  PubMed  CAS  Google Scholar 

  31. Wang DZ, Chao L, Chao J. Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension 1997; 29: 488–93

    Article  PubMed  CAS  Google Scholar 

  32. Wang C, Chao L, Chao J. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 1995; 95: 1710–6

    Article  PubMed  CAS  Google Scholar 

  33. Xiong W, Chao J, Chao L. Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension 1995; 25: 715–9

    Article  PubMed  CAS  Google Scholar 

  34. Jin L, Zhang JJ, Chao L, et al. Gene therapy in hypertension — Adenovirus-mediated kallikrein gene delivery in hypertensive rats. Human Gene Ther 1997; 8(1): 753–61

    Article  Google Scholar 

  35. Yayama K, Wang C, Chao L, et al. Kallikrein gene delivery attenuates hypertension, cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 1998; 31: 1104–10

    Article  PubMed  CAS  Google Scholar 

  36. Chao J, Zhang JJ, Lin KF, et al. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Human Gene Ther 1998; 9: 21–31

    Article  CAS  Google Scholar 

  37. Chao J, Jin L, Chen LM, et al. Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Human Gene Ther 1996; 7: 901–11

    Article  CAS  Google Scholar 

  38. Chao J, Yang ZR, Jin L, et al. Kallikrein gene therapy in newborn and adult hypertensive rats. Can J Physiol Pharmacol 1997; 75: 750–6

    Article  PubMed  CAS  Google Scholar 

  39. Wang C, Chao C, Madeddu P, et al. Central delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Biochem Biophys Res Commun 1998; 244: 449–54

    Article  PubMed  CAS  Google Scholar 

  40. Madeddu P, Parpaglia PP, Glorioso N, et al. Antisense inhibition of the brain kallikrein-kinin system. Hypertension 1996; 28: 980–7

    Article  PubMed  CAS  Google Scholar 

  41. Emanueli C, Chao J, Regoli D, et al. Role of the brain bradykinin B 1-receptor in the central regulation of blood pressure in rats [abstract]. High Blood Pressure Council Meeting, 1997: Sep 16–19; Washington, DC: P68

  42. de Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science 1986; 230: 767–70

    Article  Google Scholar 

  43. Conte G, Bellizzi V, Cianciaruso B, et al. Physiological role and diuretic efficacy of atrial natriuretic peptide in health and chronic renal disease. Kidney Int 1997; 51 (Suppl. 59): S28–32

    Google Scholar 

  44. Laragh JH. Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis. N Engl J Med 1985; 313: 1330–40

    Article  PubMed  CAS  Google Scholar 

  45. Brenner BM, Ballermann BJ, Gunning ME, et al. Diverse biological actions of atrial natriuretic peptide. Physiol Rev 1990; 70: 665–99

    PubMed  CAS  Google Scholar 

  46. Cahill PA, Hassid A. ANF-C-receptor-mediated inhibition of aortic smooth muscle cell proliferation and thymidine kinase activity. Am J Physiol 1994; 266: R194–203

    PubMed  CAS  Google Scholar 

  47. Pedram A, Razandi M, Hu RM, et al. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 1997; 272: 17097–103

    Article  PubMed  CAS  Google Scholar 

  48. Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension 1990; 16: 301–7

    Article  PubMed  CAS  Google Scholar 

  49. Simon WM, Krege JH, Oliver PM, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995; 267: 679–81

    Article  Google Scholar 

  50. Lin KF, Chao J, Chao L. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension 1995; 26: 847–53

    Article  PubMed  CAS  Google Scholar 

  51. Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy and renal injury in salt-sensitive rats. Human Gene Ther 1998; 9: 1429–38

    Article  CAS  Google Scholar 

  52. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated form human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553–60

    Article  PubMed  CAS  Google Scholar 

  53. Sakata J, Shimokubo T, Kitamura K, et al. Molecular cloning and biological activities of rat adrenomedullin, a hypotensive peptide. Biochem Biophys Res Commun 1993; 195: 921–7

    Article  PubMed  CAS  Google Scholar 

  54. Sakata J, Shimokubo T, Kitamura K, et al. Distribution and characterization of immunoreactive rat adrenomedullin in tissue and plasma. FEBS Lett 1994; 52: 105–8

    Article  Google Scholar 

  55. Hirata Y, Hayakawa H, Suzuki Y, et al. Mechanisms of adrenomedullin-induced vasodilation in the rat kidney. Hypertension 1995; 25: 790–5

    Article  PubMed  CAS  Google Scholar 

  56. Ishiyama Y, Kitamura K, Ichiki Y, et al. Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. Eur J Pharmacol 1993; 241: 271–3

    Article  PubMed  CAS  Google Scholar 

  57. Tsuruda T, Kato J, Kitamura K, et al. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension 1998; 31: 505–10

    Article  PubMed  CAS  Google Scholar 

  58. Sugo S, Minamino N, Shoji H, et al. Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-α. Biochem Biophys Res Commun 1994; 203: 719–26

    Article  PubMed  CAS  Google Scholar 

  59. Kohno M, Yokokawa K, Kano H, et al. Adrenomedullin is a potent inhibitor of angiotensin II-induced migration of human coronary artery smooth muscle cells. Hypertension 1997; 29: 1309–13

    Article  PubMed  CAS  Google Scholar 

  60. Chao J, Jin L, Lin KF, et al. Adrenomedullin gene delivery reduces blood pressure in spontaneously hypertensive rats. Hypertens Res 1997; 20: 269–77

    Article  PubMed  CAS  Google Scholar 

  61. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664–6

    Article  PubMed  CAS  Google Scholar 

  62. Huang PL, Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239–42

    Article  PubMed  CAS  Google Scholar 

  63. Matsuoka H, Nakata M, Kohno K, et al. Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 1996; 27: 14–8

    Article  PubMed  CAS  Google Scholar 

  64. Arnal JF, Amrani AI, Chatellier G, et al. Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension 1993; 22: 380–7

    Article  PubMed  CAS  Google Scholar 

  65. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in. vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci 1995; 92: 1137–41

    Article  PubMed  Google Scholar 

  66. Cable DG, O’Brien T, Kullo IJ, et al. Expression and function of a recombinant endothelial nitric oxide synthase gene in porcine coronary arteries. Cardiovas Res 1997; 35: 553–9

    Article  CAS  Google Scholar 

  67. Chen AFY, Jiang SW, Crotty TB, et al. Effects of in vivo adenoventitial expression of recombinant endothelial nitric oxide synthase gene in cerebral arteries. Proc Natl Acad Sci 1997; 94: 12568–73

    Article  PubMed  CAS  Google Scholar 

  68. Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension 1997; 30: 307–13

    Article  PubMed  CAS  Google Scholar 

  69. Uehara Y, Hirawa N, Kawabata Y, et al. Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension 1994; 24: 770–8

    Article  PubMed  CAS  Google Scholar 

  70. Murakami H, Yayama K, Chao L, et al. Human kallikrein gene delivery protects against gentamicin-induced nephrotoxicity in rats. Kidney Int 1998; 53: 1305–13

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, 29425-2211, USA

    Julie Chao, Cindy Wang & Lee Chao

Authors
  1. Julie Chao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cindy Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lee Chao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie Chao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chao, J., Wang, C. & Chao, L. Gene Therapy for Hypertension. BioDrugs 11, 43–53 (1999). https://doi.org/10.2165/00063030-199911010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199911010-00005

Keywords

Search

Navigation